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CHRISTELLE S RIGAL*
Between 1940 and 1970, medical research was transformed. In France, as well as in
Britain, this transformation has often been associated with the renewed importance
of experimental medicine. Like the actors who participated in this transformation, histor-
ians have highlighted the “biologization” of medicine that took place and was advocated
by a new generation of clinicians and fundamental biologists.
1 Together, they believed
that medicine needed greater input from virology, bacteriology, immunology, embryo-
logy and biochemistry, and required new spaces where clinical questions could be trans-
lated into experimental systems, examined and manipulated. In France, the Institut
National d’Hygiene (INH, National Institute for Health), created under the Vichy regime,
became the home institution for many researchers working on disease causation, trans-
mission, and evolution. In the 1960s, a major reform of medical teaching and organiza-
tion carried out under the presidency of General de Gaulle resulted in the creation
of dozens of hospital laboratories, which participated in these developments.
2 However,
in the eyes of French post-war medical reformers, biology was not the “single best way”
to make medicine more scientific. Another was to trust in numbers, to mobilize statistics
and quantitative tools for evaluating the effects of medical care and therapeutic interven-
tion. In contrast to the biological route, the statistical path was highly problematic,
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511meeting resistance, if not outright hostility, from clinicians, with the result that the
eventual “mathematization” of French medical research has been attributed to external
pressures, resulting either from the newly found political influence of INH statisticians,
or from the new research questions and tools imported from Britain and the United
States, where quantification in the clinic as well as in public health had long benefited
from wide support.
3 According to this perspective, in contrast to their colleagues in
Britain and the USA, French medical reformers favoured a form of biomedicine which,
despite recognizing the importance of molecules and macromolecules, was characterized
by a physiological approach to the understanding of disease and therapeutic efficacy,
and allowed clinical trials only a limited role in selecting the optimal mode of medical
intervention.
This paper examines this scenario, focusing on the example of cancer research in
France. There—as elsewhere—cancer research received impetus from public charities,
benefited from increased government funding, and took a fresh turn after the Second
World War, with new investigation into viruses, mutations, and immunological
responses. However, while French achievements in risk factor epidemiology, which
were largely due to the work of a small group of medical statisticians located within
the INH, have been widely acknowledged, the French contribution to what was the
most important change in cancer treatment, namely the rise of cancer chemotherapy in
the 1960s and 1970s, is barely remembered.
4 As a consequence, the existence of a clin-
ical path toward controlled trials, and the quantification of bedside research that accom-
panied it, has tended to be overlooked in the case of France.
In order to fill this gap in the literature and test the hypothesis that French “neo-
clinicians” created a small, but none the less significant, medical world in which biome-
dicine was synonymous with diagnosis as well as treatment, with clinical trials as well as
macromolecules, with patients as well as animal models, this paper examines
the trajectory of Jean Bernard and his co-workers. Jean Bernard was one of the
“neo-clinicians” who argued in favour of the reform of medical research in France after
the Second World War, emphasizing the need for institutional and intellectual changes
that would reinforce the role of biology and statistics in the practice of medicine. That
this was not mere rhetoric is revealed by the work on acute leukaemia carried out
by Bernard and his team at the centre for research on leukaemia and blood diseases in
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512the Ho ˆpital Saint-Louis in Paris, which took an active part in international cancer
research, and helped to establish chemotherapy as a major form of treatment for cancer
in the 1960s and 1970s.
In this context, the development of trial protocols, the use of control groups, and the
application of computational techniques were advocated as means for the production
of standards and norms that would ensure greater comparability, homogeneity, control
and “objectivity” of medical practices. However, these did not lead to a complete substi-
tution of traditional—mainly qualitative—clinical research by quantitative approaches.
By following the introduction of controlled clinical trials in one particular setting, that
of the Saint-Louis Hospital, this paper also shows that the project for modernizing and
rationalizing French medical research was in large part inspired by cancer research in
the United States, including its commitment to an industrial model of research organiza-
tion. However, paradoxically, in France this project was not based on the mounting influ-
ence of private pharmaceutical firms, but rather—in a way reminiscent of British
medicine—on state-supported quasi-universal access to health care, with its corte `ge of
massive investments, and alleged co-ordination and control.
5
My argument is developed in three parts. First, I summarize Jean Bernard’s scientific
and medical career as it exemplifies the trajectory of many French biomedical reformers.
Second, I focus on Bernard’s research on leukaemia, analysing the evolution of his clin-
ical trial methodology, and examining the relationship between this evolution and the
transformation of leukaemia research in the USA. In the last section, I relate these cog-
nitive and practical changes to the political and institutional reorganization of medical
research in 1960s France, which helped to make these changes a reality.
Jean Bernard’s Early Medical Career
Before studying Bernard’s work in Paris and following his trajectory towards
statistically based controlled clinical trials, it is worth saying a few words about his early
career. Jean Bernard was born in Paris in 1907. In 1929, he took an internship under Paul
Chevallier, a physician from the Assistance Publique des Ho ˆpitaux de Paris (APHP),
who had first qualified in dermatology and then specialized in blood disorders.
6 In
1930s France, haematology was still a minor discipline, obsessed with discussions about
nomenclature and tissue genesis, and haematological disorders were described and clas-
sified by correlating clinical signs with microscopic findings. Thus, Bernard’s first pub-
lications, which were co-authored with Chevallier, were mainly concerned with the
description and characterization of diseases of the lymphatic system. Between 1930
and 1935, Bernard also helped the paediatrician Robert Debre ´ and the veterinary surgeon
Gaston Ramon to develop a diphtheria vaccine at the Pasteur Institute.
7
5See John Stewart’s paper in this issue.
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513Bernard prepared his doctoral thesis in the laboratory of Andre ´ Lemierre, professor of
infectious diseases. Published in 1936, his MD thesis showed that the injection of coal tar
into the bone marrow of rats induced leukaemia and lymphomas.
8 These experiments
contributed to the classification of leukaemia as a neoplastic disease, thereby helping
to settle the question of its cancerous nature. During the war, Bernard worked in a surgi-
cal ambulance team, where he treated war wounds with sulphonamides. He joined the
French resistance in southern France, before serving as a physician in the army. Then,
in 1946, having passed the highly competitive examination of Me ´decin des Ho ˆpitaux
de Paris, he joined the paediatric department of the He ´rold Hospital.
During the war, the activities of paediatric departments had been profoundly trans-
formed. The introduction of penicillin and the sulphonamides revolutionized the prog-
nosis of many infectious diseases, so that the only terminally ill patients remaining in
the wards were children suffering from leukaemia or cancer. Bernard therefore chose
to concentrate on these diseases, and combine traditional bedside medicine with experi-
mental studies.
9 In 1946, having agreed to work on leukaemia with the biologist Marcel
Bessis, the latter put at his disposal a small laboratory at the Centre National de Transfu-
sion Sanguine (National Centre for Blood Transfusion), which was equipped with experi-
mental tools and animals.
10 Later, Bernard turned rooms in the cellar of the He ´rold
Hospital into a small research laboratory.
11
At that time, leukaemia was suspected when swelling of the haematopoeitic organs,
haemorrhages, pallor, and infections appeared. Microscopic examination of the patient’s
blood was necessary to confirm the diagnosis, and leukaemia sub-classification was
based on the histological study of normal white blood cells. Thus, acute leukaemia
was defined as an increase of normal mature white cells, combined with a high rate of
abnormal immature white cells in blood. However, dissatisfied with such classification,
Bernard in 1947 began reviewing the files of about 150 acute leukaemia patients in
search of more precise diagnostic criteria. As a result, he was able to show that initial
symptoms evoked acute leukaemia in only 30 per cent of the cases, and that in most
cases the bone marrow had contained many leukaemia cells (morphologically abnormal
immature white cells) even before these had appeared in the blood. Hence, he proposed
that the final diagnosis should be based on bone-marrow examination.
12 Another type of
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514research in which Bernard participated after the Second World War involved the use of
radioactive molecules. For instance, in 1952, working with the head of the Military
Health Service, he injected radiolabelled white blood cells into healthy volunteers and
patients with leukaemia in order to compare their circulation in normal and pathological
conditions.
13
In 1957, Bernard left the paediatric department at the He ´rold Hospital to head the
paediatric department at the Saint-Louis Hospital.
14 There, a new building entirely
devoted to haematological research, called the Hayem Centre, was built for him and
his team in 1960.
15
Statistics and Clinical Medicine: Local Paths to Controlled Clinical Trials
Bernard ran his first therapeutic experiment at the beginning of the 1940s, when he
injected colchicine, the alkaloid of meadow saffron, into the bone marrow of seven of
his patients. However, he found the results from this experiment unsatisfactory. Although
the state of every patient’s bone marrow had improved, in only two cases did their gen-
eral health improve, and this at best for a few months. Moreover, colchicine was difficult
to use, since it had no effect when given either orally or intravenously. Bernard made no
further attempt to treat human leukaemia until 1947.
16 His renewed efforts at treating
leukaemia reflect the “biomedicalization” of cancer that was taking place, in France as
elsewhere, and involved using chemical compounds to poison cancer cells on the one
hand, and statistically based controlled trials on the other. However, they also illustrate
the fact that the emergence of a trial culture in a French context was the product of local
circumstances stimulating biomedical reform, as well as of a new transatlantic circula-
tion of tools, results, and (less often) researchers.
It is well known that during the second half of the twentieth century, controlled clin-
ical trials became standard practice for assessing the efficacy of medical treatments.
In the 1960s and 1970s, first in the United States, and then in Europe, the randomized
controlled trial (RCT) gradually became accepted as the most objective procedure, and
after the 1962 amendments to the American Food, Drug and Cosmetics Act, became a
requirement for drug marketing authorization. Historians who have studied clinical trials
have analysed their characteristics and their gradual adoption by clinical researchers.
17
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515Most of the historical work examining the development of controlled clinical trials has
located their origin in the United Kingdom and in the United States. Moreover, it has
generally described their evolution as resulting from the simultaneous emergence of a
community of statisticians specialized in medical research, and of a group of “clinical
reformers” convinced firstly that biology and statistics are indispensable to medical pro-
gress, and secondly that therapeutic experimentation is necessary, even for “incurable”
diseases. Modern therapeutic evaluation can therefore be viewed as the product of the
convergence between the evolution of statistical concepts and methodologies, and
attempts by physician-experimenters to reduce the biases inherent in the selection of
patients.
18 However, it would be naı ¨ve to believe that the generalization of the RCT
was simply a question of methodological progress. As Harry Marks has pointed out in
the American context, such techniques as group control and randomization were pro-
moted by an unexpected alliance between e ´lite physicians, who were suspicious of
both general practitioners and drug manufacturers, and officials from the Food and
Drug Administration, anxious to control the pharmaceutical market and limit the number
of drugs without therapeutic value, in order to force the industry to organize controlled
(but not necessarily randomized) trials.
19
Many clinicians viewed those trials, in particular randomized trials, with reluctance
or even opposition. Various reasons have been put forward to explain this reluctance.
Firstly, the strength of clinical “tradition”, emphasizing the individuality of patients
and diseases as well as the importance of the physician’s experience and clinical
“judgement”, has been seen as incompatible with the population-based approach
involved in therapeutic evaluation.
20 This aspect is often related to a second explanation,
namely the physician’s lack of training in statistics, itself linked to the institutional
weakness of medical statistics.
21 Thirdly, randomization and placebos were often
considered to be unethical by clinicians because they imply giving a treatment to patients
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516without any obvious reasons for considering it effective, thereby transforming these
patients into laboratory animals.
22 Alternatively, if the treatment is to all intents and
purposes thought to be effective, then it is unethical to deny the therapy to half the
sample population.
The fact that physicians’ reluctance to adopt controlled clinical trials was eventually
overcome has been described as the consequence of practical, scientific and regulatory
factors. In the aftermath of the Second World War, interest in controlled trials was
strengthened by the large-scale release onto the medical market of more effective and
vigorously advertised pharmaceutical products, like the sulpha-drugs and antibiotics.
Under pressure from patients keen to try new treatments, but suspicious of pharmaceuti-
cal firms’ claims of efficacy, physicians began to accept clinical trials as a means of
organizing clinical judgement, strengthening their expertise, making the allocation of
drugs easier, and facilitating difficult therapeutic decisions. This trend was reinforced
in the 1960s by regulatory measures, which—in the United States at least—transformed
controlled trials into powerful administrative tools.
23
Another explanation for the eventual acceptance of controlled clinical trials by clini-
cians, which is less often mentioned but plays an important role in our story, is the estab-
lishment of laboratories within medical research institutes, which introduced the idea of
experimental control.
24 This was echoed in the books and articles written by statisticians
recruited into these institutions, which drew analogies between “basic” research and con-
trolled clinical trials in order to familiarize clinicians with medical statistics.
25 An analy-
sis of Bernard and his co-workers’ research on leukaemia demonstrates this. It also
shows important differences between the Parisian scene and American cancer research,
both in terms of trial methodology, and the ways in which this new form of medical
“scientificity” was appropriated.
Bernard’s first therapeutic experiments on humans at the beginning of the 1940s had
ended following a combination of technical difficulties and ambiguous results.
26 A few
years later, between 1947 and 1950, Bernard and Bessis treated—in a way typical of
local clinical and physiological innovation—about twenty patients with so-called exsan-
guino-transfusion, a technique for replacing nearly all a leukaemia patient’s blood with
that of donors.
27 The fact that some colleagues argued that remissions observed after
the treatment were spontaneous led them to devise quantitative criteria for contrasting
“improvements” with “partial remissions” and “complete remissions”, and for comparing
22Matthews, op. cit., note 3 above, pp. 131–8;
Marks, op. cit., note 3 above, 155–8; Kaptchuk, op.
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517the frequency of the latter with that of the “spontaneous” but complete remissions
reported in the literature.
28 According to Bernard and his colleagues, it was not possible
to argue that exsanguino-transfusion prolonged life, because the mean survival time of
untreated patients was not known precisely enough, and data varied considerably from
one specialist to another.
29 Hence the treatment was abandoned, not because it had
failed, but because it was too difficult to generalize and laboratory work was unlikely
to improve the results.
The mixed results of exsanguino-transfusion made the American alternative, namely
the chemotherapeutic use of folic acid antagonists, appear more attractive. As is well
known, Sidney Farber’s team conducted the first trials of folic acid antagonists in acute
leukaemia in Boston in 1947.
30 Some ten other groups in the United States and in Europe
rapidly began testing these compounds. No pre-established treatment protocol was used,
and the evolution of the disease in treated patients was compared with what had been
observed before potential drugs became available. In Paris, the first results obtained
with the antagonists supplied by the American firm Lederle Laboratories were not spec-
tacular; they were equivalent to those obtained with exsanguino-transfusion. However,
the use of molecules was simpler than the substitution of a patient’s blood, and chemo-
therapy was considered more promising on the grounds that specific chemicals to kill
specific cells would eventually be found. Though interesting, the results obtained by
the ten other groups were neither similar, nor even comparable. Practices differed, in
particular regarding dosage and treatment schedule. In addition, the criteria used to
assess the efficacy of folic acid antagonists were not identical; the evaluation of the
most effective molecules differed, as well as the inventory of their effects on the clinical
status of the patients. Among the reported trials, the only shared conclusion was that folic
acid antagonists were able to induce remissions.
31
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518Soon after this introduction of the folic acid antagonists, in 1950, the teams of William
Dameshek and Sidney Farber in Boston on the one hand, and of Joseph Burchenal in
New York City on the other, announced the induction of remissions in leukaemia follow-
ing the administration of the hormones ACTH and cortisone. Once again, many trials
were launched in several countries.
32 Within two years, about 250 patients had been trea-
ted worldwide. If one considers the number of patients involved, the two main groups
participating in the trials were Burchenal’s at the Memorial Hospital in New York, and
Bernard’s at the Saint-Louis Hospital in Paris. As for previous treatments, methods
and results were not easily comparable. In particular, the definition of remission still var-
ied greatly from one centre to another. Nevertheless, the different teams reached the
same conclusion: the frequency of remissions with ACTH and cortisone was equivalent
to that obtained with folic acid antagonists.
33
Although Bernard and his co-workers initially mimicked Burchenal’s practice by
using cortisone alone, they soon began combination trials using folic acid antagonists,
hormones, and transfusions to treat acute leukaemia in children. From the outset, remis-
sion rates were higher than ever before. However, as the mean duration of the disease
was not yet accurately determined, it was impossible to assert unambiguously that the
treatment prolonged life. The folic acid antagonist and the hormone were either given
together, or in succession in order to compare both methods.
34 Although the two trials
were separated by a short interval, comparison was still “historical” in nature. Then, in
1952, Bernard and his colleagues designed their first “comparative” trial. The aim was
to assess the value of cortisone for maintenance therapy—as opposed to therapies aiming
to induce remission. The children who were in remission at the Saint-Louis Hospital
were divided into three groups. Patients from the first group received the same dose of
32Jean Bernard, ‘Les essais de traitement des
leucoses aigue ¨s’, La Semaine des Ho ˆpitaux de Paris,
1950, 26 (65): 3322–35; idem, ‘Les nouveaux
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41: 285–7; Jean Bernard and Marcel Bessis,
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22: 205–33.
33O H Pearson, L P Eliel, T R Talbot Jr., J R
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Blood, 1950, 5 (8): 786–7; S Farber, V Downing, B H
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treatment of leukaemia and leukosarcoma’, Blood,
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Paris, 1951, 67 (15–16): 621–32; Bernard, ‘Les
nouveaux traitements’, op. cit., note 32 above; Jean
Bernard and Georges Mathe ´, ‘Etude des leucoses
aigue ¨s de l’enfance traite ´es par l’association
antifoliques-cortisone’, Le Sang, 1952, 23: 12–27;
Bernard and Bessis, op. cit., note 32 above.
Medical Research in Paris Hospitals after the Second World War
519cortisone during remission as during induction. Patients from the second group took
cortisone at a lower dose, and for children from the third group the hormonal treatment
was discontinued.
35
The pharmacopoeia against leukaemia was then enriched by another emblem of cancer
chemotherapy: 6-mercaptopurine. Burchenal’s team conducted the first clinical studies
with this new drug, publishing the results in 1953.
36 Within a year, about twenty Amer-
ican groups and three foreign teams, including Bernard’s, had tested this agent. Once
again, locally defined criteria rendered the different trials difficult to compare. The
assessment of the therapeutic efficacy of 6-mercaptopurine was further complicated by
the fact that some investigators gave it alone, whereas others combined it with available
drugs.
37 Given these parallel enterprises, the harmonization of assessment methods
seemed increasingly necessary. The question was debated with growing intensity at the
international level during the late 1950s. However, even in the 1960s, practices were
only partially standardized.
38
During the 1940s and 1950s, Bernard’s team conducted local, independent, therapeutic
trials. These involved small numbers of patients, ranging between ten and fifty. Inclusion
and evaluation criteria were not formally predetermined. In the first phase, which had
the object of inducing remission, no control group was used. It was the clinician’s
experience of the disease that served as the reference point. Nevertheless, despite his
extensive experience, Bernard did not always consider himself able to distinguish
between spontaneous remission and remission due to treatment.
39 Thus he continued
to use “historical” controls, the analysis of hundreds of patients’ files, which provided
him with an estimation of the frequency and duration of spontaneous remissions.
Then, at the beginning of the 1950s, Bernard and his co-workers started organizing com-
parative trials in an attempt to find therapeutic schedules capable of maintaining
remissions. They used no placebo, administering instead competing therapies to each dif-
ferent group of patients. These trials were neither randomized, nor double blind. Even
if the Parisian team compared their evaluation criteria regularly with those used by
American acute leukaemia specialists, they saw no need to align their practices with
those of their American colleagues.
We have already seen that in America, from the mid-1950s onwards, clinical trials
on acute leukaemia were conducted by the different specialized centres in a similar
way, that is to say mainly on the basis of local practices and knowledge and without
35Bernard and Bessis, op. cit., note 32 above;
Jean Bernard and G Deltour, ‘Les nouveaux
traitements des leucoses’, La Semaine des Ho ˆpitaux
de Paris, 1953, 29 (67): 3430–1.
36J Burchenal, D A Karnofsky, M L Murphy,
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37R W Miner (ed.), ‘6-mercaptopurine’, Annals of
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183–508, pp. 359–74, 385–508.
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520referring to controlled clinical trial methodology. That situation changed in 1954 with
the creation, within the National Cancer Institute (NCI), of the Cancer Chemotherapy
National Committee (CCNC). The new committee was directed by Sidney Farber, and
was responsible for co-ordinating the relationship between government, industry,
and institutions. One year later, under pressure from the United States Congress and
from oncologists outside the NCI, the Cancer Chemotherapy National Service Center
(CCNSC) was set up to replace the CCNC. The main mission of this new agency
was to supervise pharmacological and other pre-clinical tests, in addition to organizing
co-operative clinical trials, thereby bringing together the numerous American teams
and, later, foreign teams as well. Within the CCNSC, clinical trials on childhood acute
leukaemia were organized by the Acute Leukaemia Group B (ALGB), which soon
became the Cancer and Acute Leukaemia Group B (CALGB).
40 This was not a mere
change of sponsor and organization. Scaling-up had important consequences for the
practices involved and the knowledge produced, for standardization was perceived as
the condition for fruitful co-operation, transferability of results, and speed of evaluation
of candidate molecules.
The first co-operative study on leukaemia organized under the aegis of the CCNSC
involved four American centres, and included sixty-five patients who were treated
between May 1955 and October 1956. This study aimed at comparing two modes of
combination of 6-mercaptopurine and amethopterine. In the first case, the folic acid
antagonist was given continuously, and in the second, only intermittently. The results,
published in 1958, showed that remission and survival lasted longer under the continuous
regimen. Considering the methodological aspects of their study, the authors of the report,
which cited the work of the British statisticians Austin Bradford Hill and Ronald Fisher,
insisted upon the adequacy of their approach compared with the principles of the
controlled clinical trial. Patients had been paired according to their age and type of
leukaemia, before being randomly allocated to one or other treatment group. For each
type of treatment, a detailed protocol had been drawn up and strictly followed. The
authors also emphasized the ethical aspects taken into consideration when designing
the trial. They argued that this kind of trial was not prejudicial to patients, because
the median survival time obtained was similar to that recently published elsewhere in
the literature.
41
The second trial on acute leukaemia organized under the CCNSC involved eleven
American centres. Its objectives were to compare treatment with 6-mercaptopurine alone
on the one hand, with treatment combining 6-mercaptopurine and azaserine on the other.
This randomized controlled trial took place between December 1955 and March 1957,
and involved 168 patients. The protocol was elaborated in co-operation with Irwin Bross,
from Cornell University Medical College. Compared to the previous trial, its novelty lay
40Lo ¨wy, Between bench and bedside, op. cit.,
note 1 above, pp. 39, 42–7, 54–61; Peter Keating and
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1955–1966’, Bull. Hist. Med., 2002, 76: 299–334.
41E Frei III, J F Holland, M A Schneiderman,
D Pinkel, G Selkirk, E J Freireich, R T Silver, G L
Gold and W Regelson, ‘A comparative study of two
regimens of combination chemotherapy in acute
leukemia’, 1958, Blood, 13 (12): 1126–48.
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521in the fact that patients were receiving their first leukaemia therapy in the context of this
trial. No significant difference was observed between the two forms of treatment.
42
Another trial, published in 1960, used placebo and double-blind assessment. It aimed
at determining the therapeutic value of a new compound, 6-azauracil, in cases of leukae-
mia that were resistant to the usual treatments. The protocol was designed in collabora-
tion with the statistician Edmund Gehan. Paradoxically, the main conclusion reached by
this trial was that the use of a placebo was not necessarily required. Since 6-azauracil
was inactive against the disease, the trial was judged convenient for use as a control in
subsequent trials.
43
Another methodological innovation, sequential analysis, was introduced in an
ALGB study conducted in 1959 and 1960. This co-operative trial, also elaborated
with Gehan, investigated the effect of 6-mercaptopurine on the duration of the remission
induced by steroids. Patients in remission were selected at random, and were given
6-mercaptopurine or a placebo according to a double-blind procedure. When in relapse,
the patients who were given the placebo received 6-mercaptopurine. The sequential
analysis of the results allowed the trial to be stopped after remission lengths were
observed in twenty-one pairs of patients, since the benefit of a maintenance therapy
with 6-mercaptopurine had been proved. On sequential analysis, the paper referred
to the work of Peter Armitage, a collaborator of Bradford Hill. Otherwise, the authors
of the report also drew attention to the ethical value of controlled trials. They argued
that the use of a placebo had no significant effect on survival time, and that this therapeu-
tic schedule therefore allowed new products to be tested while providing the best
treatment.
44
Controlled clinical trials organized by the ALGB had, as already mentioned, very little
or no influence on the assessment of new treatments in Paris during the second half of
the 1950s. Surprisingly, they also had little impact on the practices of Burchenal’s
team, despite its participation in one of the first CCNSC trials.
45 In a trial performed
in the mid-1950s, which aimed to compare treatment with 6-mercaptopurine to treatment
with 6-chloropurine, only about forty patients participated. Moreover, the results were
compared to those of a local historical control group, and the report did not include
any references to statistical methodology, although the criteria for evaluating results
were those of the CCNSC.
46
All these observations suggest that at the end of the 1950s, local norms coexisted with
standard protocols for the conduct of therapeutic trials both in Europe and in the United
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522States. Was this also the case in the 1960s, when the NCI model of chemotherapeutic
research and the RCT standard seem to have become generalized?
Links between the Paris unit and the NCI leukaemia task forces were formalized in
the early 1960s. After Michel Boiron contacted the ALGB during a research trip to the
United States in 1962, Bernard’s team was included in the randomized co-operative
trial ALGB 6308, designed to compare the effects of 6-mercaptopurine and methotrexate
(amethopterine) in acute leukaemia in adults. In the 1960s, Bernard and his collaborators,
mainly Boiron, Claude Jacquillat, and Maryse Weil, participated in six other ALGB trials
(protocols 6503, 6601, 6603, 6606, 6706, and 6801).
47
The relationship between Bernard’s team and French medical statisticians followed
the same chronology. In the early 1960s, Bernard got in touch with statisticians in Paris,
and asked them to help with the CALGB trials. In 1962, he took advice from the
mathematician Daniel Schwartz while preparing a report on the effect of treatments on
survival. Schwartz was the leader of a small group of medical statisticians, formed in
the mid-1950s, whose members were more inclined to identify themselves with labora-
tory workers than with public health officers, and who established themselves within bio-
medical research by offering their services to “neo-clinicians”.
48 Two of his colleagues,
Robert Flamant and Philippe Lazar, were deeply involved in the development of thera-
peutic trial methodology in France.
49 However, close collaboration between Bernard
and local medical statisticians truly began only in 1966, when Nicole Feingold, a statis-
tician from the Institut National d’Hygie `ne, which had recently been renamed Institut
National de la Sante ´ et de la Recherche Me ´dicale (INSERM, the National Institute for
Health and Medical Research), joined Bernard’s institute at the Saint-Louis Hospital.
50
Publications by the Paris team show the coexistence, during the 1960s, of three types
of therapeutic trial: first, “preliminary” trials; second, “home-made” protocols designed
and conducted exclusively at the Saint-Louis Hospital; third, ALGB protocols.
51 The
“preliminary” trials of Bernard’s team used “traditional” methodology, involving a small
number of patients and historical controls, and relying on clinical experience. In contrast
47Archives Nationales, Versement 2002192,
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523to the 1950s trials, in which new drugs had first been tested on patients in relapse or non-
responsive to usual treatments, these “preliminary” trials tended to include previously
untreated patients.
52
Meanwhile, similar preliminary trials were being conducted by Burchenal’s
team, although they differed in two respects from the French ones. First, in 1967, the
American group started collecting informed consent forms from participants; second,
they continued to recruit patients in relapse.
53 When the new therapeutic agents tested
on a small scale were judged promising, they were then included in the “Paris” or
ALGB protocols. The Paris protocols were elaborated at the Saint-Louis Hospital by a
chemotherapy committee chaired by Bernard.
54 Unlike the ALGB protocols, they did
not use randomization for the evaluation of the induction of remission.
55 Randomization
was not introduced until 1966, in protocol Paris 06 LA 66, as part of maintenance
therapy, so that only half of the patients were given immunotherapy to complement
chemotherapy.
56
Although the organization of clinical trials in France seems to have been influenced by
American practices, the ALGB was not the only model used. Nor did the transfer of
knowledge and practices between centres go in only one direction, since ALGB trials
were designed to answer questions posed by “home-made” trials, including the Paris
trials. Moreover, criteria for assessing treatments resulted from convergence, rather
than alignment, with the ALGB. In 1956, the Clinical Studies Panel of the CCNSC pub-
lished criteria for the evaluation of responses to treatment in acute leukaemia. These
were: A for marrow, B for peripheral blood, C for physical findings, and D for symp-
toms. Complete remission implied a reversal to normal, both haematologically and
clinically, with a rating of 1 in all four categories (A1B1C1D1). Relapse was considered
to occur when the patient’s condition deteriorated in any category (A3B3C3D3). Other
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(NSC-32946) and 6-mercaptopurine (NSC-755) in
acute granulocytic leukemia’, Cancer Chemother.
Rep., 1965, 45: 69–73; M Boiron, M Weil, C
Jacquillat, J Tanzer, D Levy, C Sultan and J Bernard,
‘Daunorubicin in the treatment of acute myelocytic
leukemia’, Lancet, 1969, 1: 330–3; C Jacquillat,
M Weil, A Bussel, J P Loisel, T Rouesse, M J
Larrieu, M Boiron, B Dreyfus and J Bernard,
‘Treatment of acute leukemia with L-
asparaginase—preliminary results on 84 cases’,
Recent Results Cancer Res., 1970, 33: 263–78; C
Jacquillat, M Weil, M-F Gemon, G Auclerc, J-P
Loisel, J Delobel, G Flandrin, G Schaison, V Izrael, A
Bussel, et al., ‘Combination therapy in 130 patients
with acute lymphoblastic leukemia (protocol 06 LA
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524situations were called partial remissions. To qualify for an A1 rating, marrow was not
to exceed 5 per cent blast cells in adults, and 10 per cent in children.
57 This threshold
of 10 per cent was criticized by Bernard, who in 1962, having compiled 300 files of
children treated in his department between 1955 and 1960, proposed his own haematolo-
gical criteria for complete remission. For Bernard, bone marrow had to contain less than
5 per cent blast cells, even in children.
58 The Paris team therefore amended the CCNSC
criteria accordingly.
59 The same 5 per cent threshold was also adopted by the Midwest
Cooperative Chemotherapy Study Group—bringing together centres from Ohio, Iowa,
Michigan, Missouri, Illinois, Wisconsin and Indiana—for the purpose of analysing
the results of a trial published in 1964. In order to define responses to treatment with
greater accuracy, the co-operative group also modified the categories for evaluation.
Categories ABCD were replaced by MHPS (corresponding to M for marrow, H for
haematological criteria, P for physical findings, and S for symptoms). Within each cate-
gory, parameters were graded between 1 and 5. Four disease states could thus be defined:
A¼no evident disease, B¼moderate disease, C¼extensive disease, D¼extreme dis-
ease. A corresponded to a rating of 1 in all categories (M, H, P and S). Five terms
were then used to describe the response to therapy. Thus, “Improvement of disease status
A” referred to complete remission.
60
Finally, during the 1960s, the transformation of the therapeutic trials conducted
by Bernard’s team was partially inspired by the controlled clinical trial methodology
promoted by ALGB statisticians. However, the organization of clinical trials continued
to be governed mainly by local norms. This feature was not specific to France, for it
also characterized the leading American centres devoted to leukaemia research.
Thus, the Paris protocols competed with “home-made” protocols from the Memorial
Hospital, the NCI,
61 or the Detroit Children’s Hospital.
62 In the mid-1960s, discrepancies
between practices were probably seen as less problematic than during the previous
decade, because analysis of the outcomes of early chemotherapeutic trials had revealed
that a few children were living in remission for more than five years, even though
they had been treated in various ways in different centres, for different types of acute
leukaemia.
63
Just as in the 1950s, local and international norms coexisted in Europe and the
United States in the therapeutic trials in onco-haematology carried out in the 1960s.
57Harry F Bisel, ‘Criteria for the evaluation of
response to treatment in acute leukemia’, Blood,
1956, 11: 676–7.
58J Bernard, M Boiron, M Weil, J-P Le ´vy,
M Seligmann and Y Najean, ‘Etude de la re ´mission
comple `te de la leuce ´mie aigue ¨ (analyse de 300 cas)’,
Nouv. Rev. Fr. He ´matol., 1962, 2: 195–222.
59Ellison, et al., ‘Intermittent therapy’, op. cit.,
note 47 above.
60J S Hewlett, J D Battle Jr, R C Bishop, W M
Fowler, S O Schwartz, P S Hagen, J Louis, ‘Phase II
study of A-8103 (NSC -25154) in acute leukemia in
adults’, Cancer Chemother. Rep., 1964, 42: 25–8.
61E Freireich, M Karon, E Frei III, ‘Quadruple
combination therapy (VAMP) for acute lymphocytic
leukemia of childhood’, Proc. Am. Ass. Cancer Res.,
1964, 5: 20–76.
62Wolf W Zuelzer, ‘Implication of long-term
survival in acute stem cell leukemia of childhood
treated with composite cyclic therapy’, 1964, Blood,
24 (5): 477–94.
63Jean Bernard, ‘Les leuce ´mies de l’enfant’,
Pa ¨d. Fortbildungskurse, 1964, 11–12: 1–15; Joseph
H Burchenal and M Lois Murphy, ‘Long-term
survivors in acute leukemia’, 1965, Cancer Res.,
25 (9): 1491–4; Zuelzer, op. cit., note 62 above;
Jean Bernard and Marcel Bessis, ‘Peut-on gue ´rir les
leuce ´mies?’, Nouv. Rev. Fr. He ´mat., 1965, 5 (2):
209–12.
Medical Research in Paris Hospitals after the Second World War
525Nevertheless, given the changing organization of cancer clinical research in the United
States, the internationalization of the trials, and the circulation of statistical tools, these
local and international norms gradually converged. In 1959, a conference on “controlled
clinical trials”, organized by the Council for International Organizations of Medical
Sciences, was held in Vienna under the chairmanship of Austin Bradford Hill. A compar-
ison between the introductory papers co-ordinated by Hill, and the French report written
by Schwartz and his colleagues, shows very few differences. All mentioned the same
goals, ethical considerations, and methods. Thus, they agreed that retrospective con-
trols—although widely applied in the past—should be avoided, that treatments should
be allotted using tables of random sampling numbers, and that giving one drug in one
centre and a competing treatment in another, or giving different treatments concurrently
without preliminary randomization, made valid comparisons impossible. Other common
rules were the use of double-blind assessment, and the fact that the decision to enter a
patient in a trial had to be made before randomization. Both the British and the French
groups tolerated certain departures from the ideal of the controlled trial. These included
the use of the patient as his or her own control, concurrent assessment, and sequential
analysis. Moreover, clinical trials in malignant disease were considered to be peculiar
but valuable despite obvious difficulties. According to both French and British statisti-
cians, cancer trials required the use of percentage survival for a period of at least five
years as an index of curative value. Moreover, they accepted that initial treatment could
be determined by random methods and that then, at a later stage, the patient could be
given the best treatment. Lastly, double-blind trials were generally found to be imprac-
tical for cancer.
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The Clinical Vision of Medical Progress and Government Rationalization
The “experimentalization” of the clinic in France, in onco-haematology, was rooted in
political and institutional change. The general idea that medical progress depended on
the pursuit of systematic, large-scale, co-operative investigations circulated amongst
young physicians and health officials in the 1950s, and was largely accepted by the
1960s. However, the notion that medical progress was associated more specifically
with controlled trials, conducted on human subjects and investigating the activity of che-
motherapeutic agents, was invented and promoted by the physicians. As mentioned
above, the reform of medical teaching and hospital organization that was adopted in
1959 and implemented in the 1960s played a crucial role in the acceptance of this parti-
cular interpretation of biomedicine. The reform itself resulted from the alliance between
medical reformers and state administrators who believed that planning and large-scale
socio-technical programmes were the best way to rationalize and modernize French
society. Thus the ideas of “neo-clinicians” benefited from an unexpected influence
within government.
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64Controlled clinical trials, Oxford, Blackwell
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the ´rapeutiques cliniques. Me ´thode scientifique
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Organisations Internationales des Sciences
Me ´dicales, Paris, Masson, 1960.
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526On the occasion of Bernard’s seventieth birthday, Jean Hamburger wrote of Bernard’s
role and of what had inspired their self-defined and self-organized group of neo-
clinicians:
Jean Bernard has always been for me—and for many others I guess—a model. I thank the Nouvelle
Revue Fran¸ caise d’He ´matologie for offering me this unique opportunity to explain why I admire
him so much. The first reason is that Jean Bernard is a physician who is convinced that medicine
can no longer do without the method, humility, and reasoning of science. He has said that:
“contemporary medicine ... is animated by the spirit and rigour of biology ... Nothing is more
outdated than the scholastic dispute about the nature of medicine that divided those who took it
for an art, and those for whom it was a science. Medicine is assuredly a science.” Our generation
entered French medicine while it was still hesitating on that point, resisting the massive input of
chemistry, physics, and mathematics into medical research. That was when, together with some
friends, we created the Club des Treize. The Club met almost clandestinely to talk about the med-
icine we dreamt of, a medicine in which issues would be investigated with the same rigour as in
other scientific disciplines.
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The members of this Club des Treize met once a month in Robert Debre ´’s depart-
ment at the Ho ˆpital Necker. Initially, they numbered thirteen, but soon some forty phy-
sicians had been invited to join the group, which was then renamed the Cercle d’Etudes
Cliniques et Biologiques (Clinical and Biological Studies Circle).
67 Bernard often dis-
cussed the need to enrich medical research with the knowledge and practices of other
disciplines. For instance, in 1966, he observed that: “every science is measurement....
By becoming measurement, medicine ceases to be magic.” Consequently, he thought
the distinction between “clinical” and “para-clinical” examination to be unfounded, since
“what matters is not the organ that perceives the abnormalities, but the mind that inter-
prets them”.
68 Bernard also used to say that clinical observation had often stimulated bio-
logical studies, and that medical research was characterized by a “fertile double-stream”
linking data collection and experimentation.
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66“Jean Bernard a toujours e ´te ´ pour moi—et sans
doute pour bien d’autres—un mode `le. Je remercie la
Nouvelle Revue Fran¸ caise d’He ´matologie de me
donner cette occasion unique d’expliquer quelques-
unes des raisons pour lesquelles je l’admire tant. La
premie `re raison est que Jean Bernard est un me ´decin
convaincu que la me ´decine ne peut plus se passer de
la me ´thode, de l’humilite ´, du mode de raisonnement
scientifiques. Il a proclame ´ “La me ´decine
contemporaine ...est anime ´e par l’esprit, par la
rigueur de la biologie.... Rien de plus pe ´rime ´ que la
dispute scholastique sur la nature de la me ´decine
opposant ceux qui la tiennent pour un art a ` ceux qui la
tiennent pour une science. La me ´decine est
assure ´ment une science.’ La ge ´ne ´ration a ` laquelle
nous appartenons, lui et moi, avait trouve ´ une
me ´decine fran¸ caise he ´sitant encore sur ce point,
boudant l’entre ´e en force de la chimie, de la physique,
de la mathe ´matique dans la recherche me ´dicale.
C’e ´tait le temps ou `, avec quelques amis, nous
fondions le Club des Treize. Le Club se re ´unissait
presque clandestinement, pour parler de la me ´decine
dont nous re ˆvions, une me ´decine dont les proble `mes
seraient aborde ´s avec la me ˆme rigueur que celle des
autres disciplines scientifiques.” Jean Hamburger,
‘Hommages a ` Jean Bernard. Courte note qui n’a rien
d’he ´matologique sur Jean Bernard’, Nouv. Rev. Fr.
He ´matol., 1977, 18 (2): 425–8.
67Interview with Jean-Fran¸ cois Bach by Suzy
Mouchet and Jean-Fran¸ cois Picard, 2 Jan. 2001; Picard,
‘De la me ´decine expe ´rimentale’, op. cit., note 2 above.
68“Toute science est mesure.... Devenant
mesure, la me ´decine cesse d’e ˆtre magie.... ce qui
compte ce n’est pas l’organe qui recueille les
anomalies, c’est l’esprit qui les interpre `te.” Jean
Bernard, ‘Progre `sd el am e ´decine et responsabilite ´ du
me ´decin’, in Deuxie `me congre `s international de
morale me ´dicale (Paris, 24–27 May 1966), rapports
(vol. 1), Paris, Ordre national des me ´decins, 1966, pp.
261–74.
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527The members of the Club des Treize founded la Revue fran¸ caise d’e ´tudes cliniques
et biologiques (French Review of Clinical and Biological Studies) in 1956. In the first
editorial of the journal, Bernard, Hamburger, Paul Castaigne, Charles Debray, Rene ´
Fauvert, Andre ´ Lambling, Jean Mathey, Pierre Soulie ´, and Jean-Pierre Soulier all mem-
bers of the Club, expressed their views on medical research:
... medical research is different from pure clinical medicine as well as from the so-called basic
sciences. It differs from the former, not so much by the methods employed (the examination of
a blood test, of an electrical recording, or of an electrophoretic curve, is as much “clinical” as
the four classical operations of inspection, palpation, percussion, auscultation), as by a constant
attempt at induction. From the latter—the physical, biochemical, and bacteriological sciences—it
differs by a permanent human concern, medical research being immediately and directly governed
by questions arising from disease.
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Building on this concept of scientific medicine, Paris neo-clinicians gradually
developed a notion of “clinical medicine” in a broad sense. Whereas in his 1956 scien-
tific autobiography Bernard limited the section on “clinical studies in leukaemia” to
descriptions of new categories of the disease, such as “leukaemia in very young chil-
dren”,
71 in a note on his institute’s “clinical section” written in 1970, under the heading
‘Clinical studies on leukaemia’ he included chemotherapy, patient supervision, statistical
surveys, and geographical haematology.
72 Until the Second World War, “clinic” and
“clinical”, which had entered the French vocabulary 300 years before, still referred to
bedside examination.
73 However, by the end of the twentieth century, both the narrow
and the broader sense of “clinical medicine” coexisted. The first referred to what a clin-
ician does when he or she is confronted with a patient in the consulting room or at the
bedside. The second referred to any resource—whether biology, chemistry, physics,
mathematics, psychology, or sociology—which could be used for diagnosis, prognosis,
treatment and prevention.
74 By the end of the 1960s, most physicians involved in the
70“... la me ´decine de recherche diffe `re aussi bien
de la clinique pure que des sciences dites
fondamentales. De la premie `re, elle se distingue non
pas tant par les me ´thodes utilise ´es (l’examen d’une
lame de sang, d’un trace ´ e ´lectrique ou d’une courbe
d’e ´lectrophore `se est tout aussi ‘clinique’ que les
quatre ope ´rations classiques d’inspection, palpation,
percussion, auscultation) que par une constante
volonte ´ d’induction. Des secondes—sciences
physiques, biochimiques, bacte ´riologiques,—elle se
se ´pare par une constante pre ´occupation humaine, les
questions pose ´es par la maladie gouvernant
imme ´diatement et directement les recherches.”
Editorial, Revue fran¸ caise d’e ´tudes cliniques et
biologiques, 1956, 1 (1): 15.
71Bernard, op. cit., note 7 above.
72Archives Nationales, Versement 20020192,
article 1, Note sur les recherches poursuivies a ` l’UER
d’he ´matologie, 1970.
73In French, the noun clinique was introduced in
1586. The term is derived from the Latin clinice and
from the Greek klinike ˆ which means medicine
performed at the bedside. The adjective clinique
entered French vocabulary seventy years later
in the term “me ´decine clinique” (clinical medicine).
Since 1808 the noun clinique has also meant medical
teaching at the bedside and since 1814 has signified
the place where this teaching is imparted. The noun
clinique has also been used, since 1890, to denote a
place for medical care. See P Imbs (ed.), Tre ´sor
de la langue fran¸ caise. Dictionnaire de la langue
du XIXe et du XXe sie `cle (1789–1960), Paris, Editions
du CNRS-Gallimard, 1977, vol. 5, pp. 923–4;
Alain Rey (ed.), Dictionnaire historique de la langue
fran¸ caise, Paris, Dictionnaires Le Robert, 1992,
p. 434.
74Christopher Lawrence, ‘Clinical Research’, in
Krige and Pestre (eds), op. cit., note 1 above,
pp. 439–59; Christiane Sinding, ‘Biologie et
me ´decine (histoire)’, in Lecourt (ed.), op. cit., note 17
above, pp. 164–9.
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528management of medical research had adopted this broad definition of clinical research.
This is reflected in the report of a colloquium on scientific policy and biomedical
research, held in Paris in 1968, organized by UNESCO, and chaired by Bernard. During
this event, the Swedish Minister of Health, Bror Rexed, explained his view of clinical
research:
I call clinical research all research centred on patients, both in laboratories, and in hospitals. Of
course, we could simply call it biomedical research, but that would be futile since it would be dif-
ficult for a biologist to be profoundly involved in such research. The researcher must be a physi-
cian, because he must take care of patients, take responsibility for them, and treat them one way
or another. Sometimes biologists, physicists, and engineers belong to teams dedicated to resolving
clinical issues. But eventually, medical responsibility falls upon the physician.
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This vision of medical progress resonated with the political climate of the 1950s,
when state initiatives were viewed as central to the modernization of French society,
above all to the growth of its economic capacity. Rationalization, control, and govern-
ment planning were also important in health matters, since after the introduction of
Se ´curite ´ Sociale in 1945 a major responsibility of the state was to guarantee access to
care, a role for which a state-based medical research policy was deemed indispensable.
Such a vision represented a radical departure from the pre-war situation. Before the
Second World War, French medical research had attracted little financial support.
Research laboratories were rare in medical universities and hospitals. In 1946, few hos-
pital laboratories existed. They were badly equipped and mainly performed a “service
role”, i.e. routine biochemical, bacteriological, or cytological analysis. Small funds for
animals or reagents came either from universities, or from the newly created Centre
National de la Recherche Scientifique (CNRS, the National Centre for Scientific
Research), and occasionally from private associations or individuals. Instruments and
materials, which were also used for diagnosis and treatment, belonged to the hospitals.
In 1941, the Vichy government created the Institut National d’Hygiene. The resources
of this institute were, however, very limited. The INH supported only research on matters
for which the regime sought specific expertise, concerning nutrition, the physiology of
reproduction, and more importantly epidemiological investigations. After the war the
budget of the INH was still far inferior to that of the CNRS.
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In 1947, several physicians from the Assistance Publique in Paris, Bernard among them,
founded the Association pour le De ´veloppement de la Recherche Me ´dicale Fran¸ caise
(Association for French Medical Research) for the purpose of collecting charitable dona-
tions. A few years later, in 1953, the Association Claude Bernard pour le De ´veloppement
75“...je nomme recherche clinique, toutes ces
recherches centre ´es sur les malades, que ce soit dans
les laboratoires ou dans les ho ˆpitaux. On pourrait bien
su ˆr la nommer aussi simplement recherche
biome ´dicale. Cependant, cela ne serait gue `re utile, car
un biologiste aurait des difficulte ´sa ` s’engager tre `s
loin dans cette recherche. Il faut que le chercheur ici
soit me ´decin, car il doit s’occuper de malades, les
prendre sous sa responsabilite ´ et les traiter d’une
manie `re ou d’une autre. Il arrive que des biologistes,
des physiciens et des inge ´nieurs fassent partie de
d’e ´quipes attache ´es aux proble `mes de la science
clinique, mais il n’en reste pas moins que la
responsabilite ´ me ´dicale incombe a ` un me ´decin.”
Comptes rendus du Colloque sur la politique
scientifique et la recherche biome ´dicale, Paris, 26–29
fe ´vrier 1968, Paris, UNESCO, 1970, pp. 11–12.
76Archives de l’Institut Pasteur, dossier CNRS
1945–1946, Commission interministe ´rielle de la
recherche, Rapport de la sous-commission recherche
me ´dicale et the ´rapeutique; Picard, op. cit., note 2
above.
Medical Research in Paris Hospitals after the Second World War
529des Recherches Biologiques et Me ´dicales dans les Ho ˆpitaux de l’Assistance Publique a `
Paris (Claude Bernard Association for Biological and Medical Research in Paris
Hospitals) was created by a consortium of institutions, including the Paris city council,
the Department of the Seine, the CNRS, the INH, the Se ´curite ´ Sociale (the French health
service), the Assistance Publique and the Association pour le De ´veloppement de la
Recherche Me ´dicale Fran¸ caise. A proposal for this association had already been sub-
mitted to the city council in 1942, but had been rejected. The creation of the Association
Claude Bernard was made possible by the appointment of a health officer, Xavier
Leclainche, at the head of the Assistance Publique, and of a research-oriented physicist
and physician, who had met Debre ´ and Louis Pasteur-Vallery-Radot during the Resis-
tance, Louis Bugnard, at the head of the INH.
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State support for medical research intensified at the end of the 1950s. During the
Second Plan (1952–57), the French industrial planning commission (Commissariat ge ´n-
e ´ral au plan)—an institution established in 1946 to facilitate economic reconstruction—
created a special commission for scientific and technical research, which considered
issues of medically related biological investigations. In 1954, Georges Champetier,
deputy director of the CNRS, and Mr Schwob, chief inspector at the Ministry of Industry,
wrote its first general report. They suggested developing existing medical research
centres, supplying them with equipment, appointing more medical researchers, training
them in the basic sciences, and encouraging the relationship between medical research
and industry. They also proposed the creation of a structure similar to the British Medical
Research Council. Finally, they considered the standardization of laboratory animals
and therapeutic molecules, such as antibiotics and hormones, to be an urgent task.
The creation of a national centre for scientific equipment and of a general biblio-
graphic service were also part of their modernization plan.
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However, such structures were not established until the end of the decade, after
Charles de Gaulle had seized power and his government turned science policy into
a national priority and scaled-up its investment in research. One exemplary initiative
was the creation of an interdepartmental administration for the promotion of scientific
and technical research created in 1958. This De ´le ´gation ge ´ne ´rale targeted a few domains
requiring emergency support. Nine committees (comite ´s d’actions concerte ´es) were
created with a handful of scientists in charge of each programme. Cancer and leukaemia
were among the chosen fields.
79 The need for extraordinary funding was justified
by contrasting public expenditure on medical research in France with that of the United
States and Great Britain: in 1959, the budget of the INH was 7 million francs, the budget
of the British Medical Research Council the equivalent of 49 million francs, while
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530the US Congress awarded 750 million francs to the National Institutes of Health in that
same year.
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The Cancer and Leukaemia Committee began work in 1960 with eleven members,
including Jean Bernard and Marcel Bessis. The allocation of funds started in July
1961. The committee selected three forms of intervention: support for research on cancer
cell and tumour growth; provision of specific training in cancer research; and the crea-
tion of laboratories and purchase of equipment. According to the committee, the study
of cancer at the cellular and molecular levels was essential, high hopes being placed
on the development of biochemistry and electron microscopy. However, the committee
refused to support therapeutic trials. Moreover, the search for chemotherapeutic com-
pounds was explicitly rejected on the grounds that it necessitated vast structures of the
kind only American institutes could afford. The Cancer and Leukaemia Committee
funded French teams on the basis of their reputation, and over a wide range of cancer
research to minimize competition between teams. In 1961, the decision was made to
fund thirteen research centres, to train 100 researchers, and to create two new institutes
and six research units.
81
Immediately after the war, the creation of laboratories within hospitals had been
hindered by the situation of physicians, who spent only part of their time in the hospital,
and the rest either in the university or in private practice, with the result that few advo-
cated the creation of teaching hospitals. However, in 1959, President de Gaulle chose
Michel Debre ´, son of Robert Debre ´, as his prime minister. Under these circumstances,
the reform of medical education, which the latter had been advocating for decades,
was at last realized. This reform eliminated the dual nature of French medical careers,
previously shared between university and hospital. Under the new arrangements, hospi-
tals and medical schools were to be jointly responsible for medical care, teaching, and
research, and were to reorganize all their services in order to implement this triple mis-
sion. The hospital and academic careers of physicians were merged. Each hierarchical
level became characterized by two titles and two functions. Geographic concentration
lay at the heart of the project, with a view to promoting interdisciplinary collaboration
and increased efficiency. The medical reform plan was implemented in 1963.
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Within a few years, encouraged by these institutional changes, Bernard no longer
considered it a good policy to let American teams do most of the research in cancer
chemotherapy. In preparation for the Sixth Plan, which was to begin in 1970, he
requested the creation of another committee to support four or five teams conducting
original research on the subject. By then, chemotherapy was not only seen to be the
core of therapeutic research, it was also perceived as a set of questions, resources, and
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531tools which “basic” molecular biologists could use to explore cellular growth and cell
differentiation.
83
French Post-war Medical Research: Foreign Models and Local Practices
The introduction of biological and statistical practices profoundly altered the
kind of medical research performed by clinicians from the Assistance Publique des
Ho ˆpitaux de Paris after the Second World War. The French medical reformers who
called themselves “neo-clinicians” advocated a form of medical research that was not
strictly biomedical in the sense of the transfer of biological knowledge and practices
into medicine, but rather consisted in the conjunction of two different scientific tradi-
tions, the first biological, the second clinical. As many observers have noted, the post-
war biologization of medical research was based on the development of the life sciences
in particular, which promoted “fundamental” studies of cells and molecules.
84 During
the late 1950s and the 1960s, this trend coincided with the establishment of autonomous
biological research laboratories within hospitals, and with what might be thought of as
the “mathematization” of clinical research, involving the mobilization of big numbers
and statistical tools. However, the gradual transformation of the clinical trials carried
out by Bernard and his team reveals that this development was in fact a re-birth of
the clinic, a long-term process now perceived as the advent of evidence-based medicine,
which, by encouraging the production of standards and norms, led to a greater homoge-
neity and greater control of medical practice. The development of protocols, the
use of control groups, the concern for quantification, and statistical analysis were
all means to this end. During the post-war period, the therapeutic trials conducted
by Bernard’s team thus involved a growing number of patients, protocols became forma-
lized, statisticians contributed to their design and to the evaluation of results, and the
Parisian group finally participated in international multi-centre clinical trials. This evolu-
tion was closely linked to organizational changes within hospitals, which were becoming
places of high-tech and specialized medical intervention required to maintain the health
of (almost) the entire nation now included in a general social security system.
Although a culture of controlled human experimentation, based on the mobilization
of statistics, and promoting the ideal of the RCT, gradually took root within Paris
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532hospitals, the example of Bernard shows that this change was less radical than is often
claimed. Although controlled trial protocols, standards of practice, and statistical
tools dominated the methodological discourses of medical reformers, they did not simply
replace more traditional forms of aggregating and comparing cases. Several types of
trials coexisted and were combined, with and without control groups, with or without
mandatory and standardized protocol, some with large, some with smaller numbers
of patients. Rather than representing a radical departure from biographical medicine, or
an acculturation to evidenced-based medicine, the path to modernization followed at
the Saint-Louis Hospital was, in fact, a process of superimposition. Although by the
late 1960s a new hierarchy of evidence had emerged, which favoured the RCT as a
collective norm if not as a routine, unlike similar developments in the United States
and in Britain, and in contrast to the prevailing historiography, its advent in France
owed little to statisticians.
Given the leading role that American specialists played in the post-war development
of cancer chemotherapy, it might be thought that change in Paris took place largely in
order to copy and adapt the American model. The existence of such a model, as well
as the circulation of molecules, protocols, results, and researchers between the USA
and France did play an important role in Bernard’s research trajectory. One outcome
of such circulation was the gradual integration of the work done at the Saint-Louis
Hospital with a transatlantic community of cancer “trialists” co-ordinated by the NCI.
However, it would be misleading to suppose either that American cancer research was
an unchallenged model, or that exchanges were one sided. The alignment of Parisian
research with research on the other side of the Atlantic was patchy, and the result of con-
vergence rather than imitation. A paradoxical aspect of the complex relationship that
connected cancer specialists in France and the USA was that the obligatory theoretical
point of reference remained the work of the Medical Research Council’s group of statis-
ticians, even if the therapeutic trials were conducted in collaboration with American, not
with British, institutions.
One final observation concerns the political support won by this “new” form of
medical research in the 1960s. While discussing this success, contemporary observers
as well as active participants variously stressed the pressing need for medical moderniza-
tion, the neo-clinicians’ power as a pressure group, and the decisive impulse which poli-
tical change in 1958 lent to the idea of institutional reform. One previously unnoticed
factor revealed by this study is the ideal of co-ordination, control, and standardization
which characterized the new cancer chemotherapy. In the United States this culture
had strong roots in the pharmaceutical industry, which not only provided the CCNSC
with molecules, but also with organizational models.
85 In the French context, this was
not an industrial culture, but an administrative one. During the so-called Trente Glor-
ieuses (the thirty years of economic growth between 1945 and 1975), social management
was seen as a state affair, planning was considered indispensable, and its administrative
85Robert F Bud, ‘Strategy in American cancer
research after World War II: a case study’, Soc. Stud.
Sci., 1978, 8 (4): 425–59.
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533implementation was accompanied by a swathe of dispositifs, which were put in place for
measuring, quantifying, standardizing, co-ordinating, and enforcing co-operation
between social and economic actors. These were mirrored in the controlled clinical trials
and other organizational tools developed by the neo-clinicians of the Assistance Publique
des Ho ˆpitaux de Paris after the Second World War, among whom Jean Bernard was a
key and influential player.
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